CRIS Current Research Information System

PINNA, ANTONIO DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.274
AS - Asia 26.265
EU - Europa 20.007
AF - Africa 1.785
SA - Sud America 1.583
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 14
Totale 82.962
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.006
VN - Vietnam 8.032
SG - Singapore 7.042
CN - Cina 6.101
GB - Regno Unito 5.603
DE - Germania 2.752
IT - Italia 2.334
SE - Svezia 2.275
HK - Hong Kong 1.615
IN - India 1.509
FR - Francia 1.463
RU - Federazione Russa 1.219
UA - Ucraina 1.177
BR - Brasile 1.141
IE - Irlanda 837
ZA - Sudafrica 567
JP - Giappone 449
NL - Olanda 445
EE - Estonia 427
FI - Finlandia 355
CI - Costa d'Avorio 345
TG - Togo 341
CH - Svizzera 298
KR - Corea 238
SC - Seychelles 234
BG - Bulgaria 214
AR - Argentina 196
JO - Giordania 175
NG - Nigeria 150
CA - Canada 146
PH - Filippine 135
BD - Bangladesh 128
TH - Thailandia 123
BE - Belgio 113
IQ - Iraq 99
AT - Austria 85
EC - Ecuador 85
PL - Polonia 81
ID - Indonesia 78
ES - Italia 77
TR - Turchia 75
MX - Messico 74
PK - Pakistan 71
IR - Iran 61
SA - Arabia Saudita 57
GR - Grecia 56
TW - Taiwan 55
CL - Cile 46
UZ - Uzbekistan 37
CO - Colombia 36
RO - Romania 36
MY - Malesia 33
MA - Marocco 29
LB - Libano 28
HR - Croazia 27
AU - Australia 26
LT - Lituania 24
PE - Perù 24
VE - Venezuela 21
EG - Egitto 20
ET - Etiopia 20
PY - Paraguay 18
KE - Kenya 15
AE - Emirati Arabi Uniti 14
NP - Nepal 14
DK - Danimarca 13
DZ - Algeria 13
NO - Norvegia 13
AL - Albania 12
AZ - Azerbaigian 12
CZ - Repubblica Ceca 12
TN - Tunisia 12
UY - Uruguay 12
DO - Repubblica Dominicana 11
OM - Oman 10
CR - Costa Rica 9
IL - Israele 9
PS - Palestinian Territory 9
JM - Giamaica 8
KZ - Kazakistan 8
PT - Portogallo 8
EU - Europa 7
KH - Cambogia 7
MD - Moldavia 7
SI - Slovenia 7
SK - Slovacchia (Repubblica Slovacca) 7
SN - Senegal 6
LK - Sri Lanka 5
MK - Macedonia 5
NZ - Nuova Zelanda 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AO - Angola 4
GE - Georgia 4
GH - Ghana 4
HU - Ungheria 4
KW - Kuwait 4
LV - Lettonia 4
LY - Libia 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
Totale 82.874
Salva come PNG Salva come JPEG
Città #
Southend 5.014
Singapore 4.780
Fairfield 3.993
Ashburn 3.265
Chandler 2.306
Woodbridge 1.988
Dong Ket 1.785
Houston 1.742
Wilmington 1.728
Seattle 1.603
Ho Chi Minh City 1.568
Hong Kong 1.534
Cambridge 1.427
San Jose 1.291
Hanoi 1.278
Santa Clara 1.252
Princeton 1.203
Ann Arbor 1.053
Dublin 786
Beijing 734
Boardman 664
Jacksonville 658
Nanjing 561
Lauterbourg 559
Westminster 530
Padova 481
Hefei 453
Bologna 441
Tokyo 399
Los Angeles 376
Berlin 367
Abidjan 345
Lomé 341
Helsinki 307
Dallas 304
New York 281
Jinan 272
Saint Petersburg 268
Bern 256
Shenyang 254
Buffalo 240
San Diego 233
Haiphong 223
Munich 220
Da Nang 217
Sofia 212
Changsha 179
Amman 170
Nanchang 167
Hebei 165
Dearborn 164
Seoul 164
Redondo Beach 158
Frankfurt am Main 156
Milan 156
Turin 151
São Paulo 146
Florence 139
Guangzhou 139
Mülheim 139
Medford 134
Tianjin 125
Abeokuta 118
Shanghai 116
Jiaxing 114
Menlo Park 112
Brussels 109
Council Bluffs 108
Delhi 105
Zhengzhou 103
Bremen 100
The Dalles 95
Hangzhou 94
Falls Church 93
Norwalk 93
Redmond 86
Johannesburg 83
Hải Dương 82
Redwood City 81
Olalla 78
Des Moines 77
Phoenix 77
Biên Hòa 74
Ningbo 69
Can Tho 67
Toronto 67
Mahé 63
London 62
Chicago 60
Haikou 60
Lanzhou 60
Falkenstein 59
Yubileyny 56
Fuzhou 55
Rome 54
Thái Nguyên 52
Vienna 52
Orem 51
Baghdad 50
Wuhan 50
Totale 55.229
Salva come PNG Salva come JPEG
Nome #
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 510
Hepatobiliary Scintigraphy in the Preoperative Evaluation of Potential Living Liver Donors 497
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis 396
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 335
A comprehensive analysis on expected years of life lost due to pancreatic cancer 309
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 303
Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome 301
Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy 281
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C 278
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 277
Prognostic criteria for postoperative mortality in 170 patients undergoing major right hepatectomy 269
Hypothermic Oxygenated New Machine Perfusion System in Liver and Kidney Transplantation of Extended Criteria Donors:First Italian Clinical Trial 269
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array 267
A new liver transplant priority for patients with hepatocellular carcinoma. 263
Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. 257
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 254
Burnout and psychological distress between surgical and non-surgical residents 254
A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. 254
Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients 253
Antifungal prophylaxis in liver transplant recipients: one size does not fit all 252
Infections in liver and lung transplant recipients: A national prospective cohort 251
Comprehensive surgical intestinal rescue and transplantation program in adult patients: Bologna experience. 246
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 243
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 238
Surgical therapy for hepatolithiasis: a Western experience. 237
Combined liver-kidney transplantation: the experience of the University of Bologna and the case of preoperative positive cross-match. 236
Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques. 235
Anticorpi anti-HLA preformati e Trapianto Combinato Rene-Fegato. Caso clinico. 234
Causes of early acute graft failure after liver transplantation: analysis of a 17-year single-centre experience. 233
A partnership model between high- And low-volume hospitals to improve results in hepatobiliary pancreatic surgery 227
Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations 227
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 225
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 225
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. 221
A Multicentric Study on Double Kidney Transplantation 220
Bacterial translocation in adult small bowel transplantation 219
Abdominal wall transplantation with microsurgical technique 219
Long-term endoscopic follow-up in small bowel transplant recipients: single-center series. 218
Combined kidney-liver, heart-liver, and kidney-pancreas transplantations from a single deceased donor. 218
Liver as a Source for Thymidine Phosphorylase Replacement in Mitochondrial Neurogastrointestinal Encephalomyopathy 218
A matched pair analysis of multicenter longterm follow-up after split-liver transplantation with extended right grafts 218
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. 217
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma 217
Multimodal Surgical Approach for Adult Patients With Chronic Intestinal Pseudo-Obstruction: Clinical and Psychosocial Long-term Outcomes 217
DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods 216
Combined liver–dual kidney transplant: Role in expanded donors 215
Blood monitoring of granzyme B and perforin expression after intestinal transplantation: considerations on clinical relevance. 213
An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. 213
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 213
Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation:a management challenge 212
A new liver extracorporeal device (LEONARDO) to treat swine with post-resection acute liver failure 211
Acute cellular rejection monitoring after interstinal transplant: utility of serologic markers and zoom videoendoscopy as support of conventional biopsy and clinical findings. 211
COMBINED KIDNEY LIVER TRANSPLANTATION: A SINGLE CENTER EXPERIENCE 210
Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation? 210
Reliability of imaging techniques in assessing portal venous thrombosis in patients with hepatocellular carcinoma candidates for liver transplantation 210
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective 209
Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pre-transplant Radiology 209
Combined heart and liver transplantation for familial amyloidotic polyneuropathy. 208
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 208
ITA-MNGIE: an Italian regional and national survey for mitochondrial neuro-gastro-intestinal encephalomyopathy. 208
Coping strategies in intestinal transplantation 208
Affidabilità della combinazione di angioecografia perfusionale ed altre tecniche di imaging nella valutazione della trombosi portale in pazienti con epatocarcinoma (HCC) candidati al trapianto di fegato 208
Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: Towards tailoring of therapeutic strategies? 208
Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. 207
Associated benign liver tumors in idiopathic granulomatous hepatitis: a case report 207
Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. 207
Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation. 205
Abdominal wall defect repair with biological prosthesis in transplanted patients: single center retrospective analysis and review of the literature 205
Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center 205
Increase of portal blood oxygenation by artero-venous shunt in diabetic rats 205
Application of a fluorescent PCR method for molecular diagnosis of posttransplant lymphoproliferative disorders on routine tissue sections. 204
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 204
Analysis of risk factors for early hepatic artery thrombosis after liver transplantation. Possible contribution of reperfusion in the early morning. 203
Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. 203
Pre-transplant psoas muscle density as a ready-to-use and low-cost predictor of patient survival after liver transplant 202
Anatomic variations of intrahepatic bile ducts in a European series and meta-analysis of the literature. 202
Italian experience in adult clinical intestinal and multivisceral transplantation: 6 years later. 202
Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. 201
Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. 201
Prediction of Three-Year Outcome of Renal Transplantation from Optimal Donors versus Expanded Criteria Donors. 200
Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study 199
Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. 198
Conventional split liver transplantation for two adult recipients: a recent experience in a single European center 198
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. 198
Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients. 198
Trapianto Combinato Rene-Fegato: Esperienza del Policlinico S.Orsola di Bologna 197
Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection. 197
Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. 196
Transcatheter Embolization for Giant Splenic Artery Aneurisms: Still an Open Question 196
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 195
Survival after the diagnosis of de novo malignancy in liver transplant recipients 195
Combined liver-kidney transplantation-s. Orsola experience: nephrological aspects. 195
Genomic allelotyping for distinction of recurrent and de novo hepatocellular carcinoma after orthotopic liver transplantation 194
Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 194
Induction therapy with Alemtuzumab (Campath) in combined liver-kidney transplantation: University of Bologna experience. 193
Combined heart-liver transplantation: A single-center experience 193
Combined Liver-Kidney Transplantation With Preformed Anti-HLA Antibodies: A Case Report. 193
Liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical long-term follow-up and pathogenic implications 193
Analysis of 80 dual-kidney transplantations: a multicenter experience. 193
Assessment of donor steatosis in liver transplantation: is it possible without liver biopsy? 192
Totale 22.908
Salva come PNG Salva come JPEG
Categoria #
all - tutte 217.603
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 217.603
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.606 0 0 0 0 0 0 0 0 0 371 333 2.902
2021/20229.997 1.003 403 591 794 955 535 236 630 356 507 2.252 1.735
2022/202310.182 1.139 1.611 579 1.339 621 704 268 551 1.767 241 859 503
2023/20242.442 201 478 121 263 170 507 117 173 83 171 71 87
2024/202510.237 425 1.858 822 764 1.896 521 608 254 123 652 258 2.056
2025/202622.443 2.407 1.967 2.222 1.663 2.735 1.669 2.464 851 4.858 1.607 0 0
Totale 84.281